Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma.

10 Dec 2007

Multiple myeloma clinical trial shows distinct survival benefit with lower dose of steroids

Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported today by S. Vincent Rajkumar, M.D. at the American Society of Hematology's annual meeting.

10 Dec 2007

Scientists develop optical device that allows them to peer through the eyes of a mouse and monitor cells passing in bloodstream

A team of researchers from the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) have developed an optical device that allows them to peer through the eyes of a mouse and monitor the cells passing through its bloodstream.

4 Dec 2007

Researchers transfer immune response to myeloma patient

Researchers at the University of Arkansas for Medical Sciences (UAMS) have for the first time transferred an immune response in a healthy individual to a patient with multiple myeloma, a cancer of the bone marrow, showing promise for cancer vaccination.

27 Nov 2007

Oral drug sets a new survival standard for bone marrow cancer

Findings from two large, international clinical trials show "unprecedented" survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow.

21 Nov 2007

Lenalidomide - dexamethasone combination effective against multiple myeloma

Pairing a new thalidomide derivative with a steroid slows progress of multiple myeloma, an incurable bone marrow cancer, and prolongs the lives of patients who have relapsed from previous treatment, researchers report in the Nov. 22 New England Journal of Medicine.

21 Nov 2007

Bortezomib pushes cancer cells into overdrive, so that they self-destruct

University of Michigan Comprehensive Cancer Center researchers have discovered that bortezomib, a promising cancer drug, is able to strike a blow against melanoma tumor cells by revving up the action of a cancer-promoting gene.

21 Nov 2007

Hormone norepinephrine may hasten the progression of certain blood cancers

Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.

20 Nov 2007

UK study looks at obesity in women

The study shows that overweight and obese women in the UK are at a higher risk of developing and dying from cancer.

6 Nov 2007

Cancer risks for overweight women

Half of all cases of womb cancer and a type of oesophageal cancer in women are caused by being overweight or obese, according to a new report published online in the British Medical Journal.

6 Nov 2007

Studies attribute recent increase in multiple myeloma survival to novel therapies

Multiple myeloma is one of the most common and devastating bone marrow cancers in the U.S., but survival rates have risen dramatically over the past decade.

2 Nov 2007

Panzem (2-methoxyestradiol ) drug a possible candidate for breast cancer treatment

A Mayo Clinic study of a drug that has shown promise in treating sarcoma, lung and brain cancers, demonstrates that the drug may also be effective in treating breast cancer, in particular the spread of breast cancer.

2 Nov 2007

Test gives insight into prognosis in patients with plasma cell malignancies

A new Mayo Clinic study due to be presented at the annual meeting of the American Society of Human Genetics in San Diego this week shows that a chromosome test called “FISH” is better than conventional methods in identifying chromosomal genetic abnormalities associated with plasma cell malignancies.

24 Oct 2007

Thalidomide therapy helps elderly myeloma patients live longer

The drug thalidomide is making a comeback as a cancer fighting therapy and has been successfully used along with standard therapy to treat the blood cancer myeloma.

7 Oct 2007

Daisy compound used to attack cancer stem cells

A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood.

2 Oct 2007

Gene profiling can single out the worst cases of multiple myeloma and guide therapy

Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide therapy in the future.

18 Sep 2007

C-reactive protein shown to be a potential target for cancer treatment

Scientists report that a protein best known as a common marker of inflammation plays a key role in the progression of human cancer.

11 Sep 2007

Mechanism identified that plays a critical role in multiple myeloma cell cycle and survival

Researchers at Emory University's Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival.

11 Sep 2007

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Celgene International Sarl has announced that it's oral cancer drug, Revlimid (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

5 Sep 2007

New anti-cancer drug made from corn lillies kills brain tumor stem cells

A drug that shuts down a critical cell-signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows.

30 Aug 2007